John G. Kelton

John G. Kelton's AcademicInfluence.com Rankings

John G. Kelton

Medical

#315

World Rank

#455

Historical Rank

Hematology

#12

World Rank

#13

Historical Rank

medical Degrees

Download Badge

Medical

Why Is John G. Kelton Influential?

(Suggest an Edit or Addition)

According to Wikipedia, John G. Kelton, M.D., FRCPC, C.M. is a Canadian hematologist and the past Dean of the McMaster University Medical School and the Dean and Vice-President of the McMaster Faculty of Health Sciences. He completed his 15-year term in June 2016 and is currently the Executive Director of the Michael G. DeGroote Initiative for Innovation in Healthcare at McMaster University in Hamilton. He is an expert on heparin-induced thrombocytopenia. He is known for developing a diagnostic test for heparin-induced thrombocytopenia in 1986.

(See a Problem?)

John G. Kelton's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. (1995) (2216)
Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. (1991) (1634)
Comparison of Plasma Exchange With Plasma Infusion in the Treatment of Thrombotic Thrombocytopenia Purpura (1992) (1025)
A 14-year study of heparin-induced thrombocytopenia. (1996) (865)
Temporal aspects of heparin-induced thrombocytopenia. (2001) (746)
Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia (2001) (649)
Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura (2007) (545)
Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. (1994) (498)
Fetal thrombocytopenia and its relation to maternal thrombocytopenia. (1993) (494)
Heparin-induced thrombocytopenia: laboratory studies. (1988) (481)
The role of the plasma from platelet concentrates in transfusion reactions. (1994) (476)
The Pathogenesis of Venous Limb Gangrene Associated with Heparin-Induced Thrombocytopenia (1997) (459)
Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. (2003) (445)
Impact of the patient population on the risk for heparin-induced thrombocytopenia. (2000) (413)
Heparin-associated thrombocytopenia. (1984) (388)
A diagnostic test for heparin-induced thrombocytopenia (1986) (385)
The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. (1982) (367)
Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. (1994) (362)
A diagnostic test for heparin-induced thrombocytopenia. (1986) (361)
Quantitative interpretation of optical density measurements using PF4‐dependent enzyme‐immunoassays (2008) (322)
Impact of the patient population on the risk for heparin-induced thrombocytopenia (2000) (322)
An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. (2003) (317)
Frequency and mechanism of neonatal thrombocytopenia. (1986) (294)
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. (2005) (273)
Incidentally detected thrombocytopenia in healthy mothers and their infants. (1988) (265)
Congenital Thrombophilic States Associated with Venous Thrombosis: A Qualitative Overview and Proposed Classification System (2003) (258)
A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. (2003) (258)
Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? (2005) (253)
Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis (2001) (246)
Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review (2015) (222)
Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis (2001) (219)
Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. (2005) (218)
Treatment of heparin-induced thrombocytopenia: a critical review. (2004) (205)
Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. (1992) (201)
Management of idiopathic thrombocytopenic purpura in pregnancy. (2000) (197)
Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. (2000) (195)
Heparin‐induced thrombocytopenia and thrombosis: clinical and laboratory studies (1993) (189)
Thrombogenic effect of high-dose aspirin in rabbits. Relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity. (1978) (186)
Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. (2001) (184)
Heparin-induced thrombocytopenia: a historical perspective. (2008) (177)
A prospective study of the usefulness of the measurement of platelet-associated IgG for the diagnosis of idiopathic thrombocytopenic purpura. (1982) (173)
Clinical impact of neonatal thrombocytopenia. (1987) (173)
The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. (2013) (166)
Studies of the immune response in heparin-induced thrombocytopenia. (2009) (165)
Bleeding associated with antithrombotic therapy. (1980) (163)
Autoimmune platelet destruction: idiopathic thrombocytopenic purpura. (1982) (162)
A prospective study of protein‐specific assays used to investigate idiopathic thrombocytopenic purpura (1999) (161)
A prospective study to determine the frequency and clinical significance of alloimmunization post‐transfusion (1995) (160)
A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. (2008) (152)
Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia. (1984) (149)
Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review (2009) (148)
Immune-mediated thrombocytopenia of malaria. (1983) (147)
The epitope specificity of heparin‐induced thrombocytopenia (1996) (144)
Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. (1991) (143)
Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia (2021) (142)
Approach to the diagnosis and management of drug-induced immune thrombocytopenia. (2013) (137)
Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. (2005) (132)
Elevated platelet-associated IgG in the thrombocytopenia of septicemia. (1979) (131)
Pregnancy in Patients With Idiopathic Thrombocytopenic Purpura: Assessing the Risks for the Infant at Delivery (1993) (130)
Gestational thrombocytopenia. (1999) (128)
The platelet serotonin‐release assay (2015) (126)
A diagnostic test for heparin‐induced thrombocytopenia: detection of platelet microparticles using flow cytometry (1996) (126)
Low fetal risks in pregnancies associated with idiopathic thrombocytopenic purpura. (1990) (120)
Heparin and platelets. (1990) (112)
High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. (2016) (112)
Frequency of Heparin‐Induced Thrombocytopenia in Critical Care Patients (2003) (111)
A systematic evaluation of laboratory testing for drug‐induced immune thrombocytopenia (2013) (110)
Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia (2021) (105)
Idiopathic thrombocytopenic purpura complicating pregnancy. (2002) (105)
The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. (2005) (103)
Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists (2013) (102)
A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. (2012) (98)
High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. (1997) (97)
Drug-induced platelet destruction. (1982) (95)
The detection of a platelet-agglutinating factor in thrombotic thrombocytopenic purpura. (1984) (91)
A prospective study investigating the mechanism of thrombocytopenia in preeclampsia. (1987) (88)
Activation of platelets by sera containing IgG1 heparin-dependent antibodies: an explanation for the predominance of the Fc gammaRIIa "low responder" (his131) gene in patients with heparin-induced thrombocytopenia. (1997) (86)
Infection-induced thrombocytopenia. (1982) (86)
An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. (1996) (86)
Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles. (1992) (86)
Studies on the frequency of heparin-associated thrombocytopenia. (1984) (86)
Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. (2015) (84)
Plasma glycocalicin. An aid in the classification of thrombocytopenic disorders. (1987) (83)
Investigation of the mechanisms of monoclonal antibody-induced platelet activation. (1991) (76)
Sex differences in the antithrombotic effects of aspirin. (1978) (75)
The use of in vitro technics to study drug-induced pancytopenia. (1979) (75)
Platelet‐activating immune complexes identified in critically ill COVID‐19 patients suspected of heparin‐induced thrombocytopenia (2021) (74)
A Platelet Function Defect in Preeclampsia (1985) (73)
Drug-induced thrombocytopenia is associated with increased binding of IgG to platelets both in vivo and in vitro. (1981) (73)
Factor V Is Complexed with Multimerin in Resting Platelet Lysates and Colocalizes with Multimerin in Platelet α-Granules (*) (1995) (73)
Heparin-induced thrombocytopenia. (2007) (72)
Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin. (1981) (72)
Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. (2017) (71)
Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. (2011) (70)
Gova/b alloantigen system on human platelets. (1990) (69)
Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura (1990) (69)
The cDNA Sequence of Human Endothelial Cell Multimerin (1995) (68)
The IgG subclasses of platelet‐associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura (2003) (67)
Investigation of the mechanisms of monoclonal antibody-induced platelet activation (1991) (67)
Thrombocytopenia in pregnancy: diagnosis, pathogenesis and management. (1996) (65)
Multimerin is found in the alpha-granules of resting platelets and is synthesized by a megakaryocytic cell line. (1993) (64)
Somatostatin treatment for cryptosporidial diarrhea in a patient with the acquired immunodeficiency syndrome (AIDS). (1988) (64)
The direct assay for platelet-associated IgG (PAIgG): lack of association between antibody level and platelet size. (1979) (64)
Heparin-induced thrombocytopenia: an overview. (2002) (63)
Laboratory abnormalities in thrombotic thrombocytopenic purpura (1998) (63)
Diagnosis and management of neonatal alloimmune thrombocytopenia. (2008) (62)
The relationship among platelet-associated IgG, platelet lifespan, and reticuloendothelial cell function (1984) (62)
Distinguishing between anti–platelet factor 4/heparin antibodies that can and cannot cause heparin‐induced thrombocytopenia (2015) (61)
Management of the Pregnant Patient with Idiopathic Thrombocytopenic Purpura (1983) (61)
p-155, a multimeric platelet protein that is expressed on activated platelets. (1991) (61)
A prospective comparison of four techniques for measuring platelet‐associated IgG (1989) (61)
Thrombocytopenia in preeclampsia and eclampsia. (1982) (60)
Characterization and localization of the Gova/b alloantigens to the glycosylphosphatidylinositol-anchored protein CDw109 on human platelets. (1995) (58)
Comparison of two direct assays for platelet-associated IgG (PAIgG) in assessement of immune and nonimmune thrombocytopenia. (1980) (57)
Calcium-dependent cysteine protease activity in the sera of patients with thrombotic thrombocytopenic purpura. (1987) (57)
Heparin-induced thrombocytopenia. (1986) (56)
IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life (2004) (54)
Current options for the treatment of idiopathic thrombocytopenic purpura. (2007) (53)
Quantitation of red cell‐associated IgG using an immunoradiometric assay (1984) (53)
Alloimmune thrombocytopenia after organ transplantation. (1999) (53)
Nonheparin anticoagulants for heparin-induced thrombocytopenia. (2013) (51)
Vaccination-Associated relapse of immune thrombocytopenia. (1981) (51)
Multimerin: a series of large disulfide-linked multimeric proteins within platelets. (1991) (51)
Thrombocytopenia caused by passive transfusion of anti-glycoprotein Ia/IIa alloantibody (anti-HPA-5b). (1992) (50)
Sex-related differences in platelet aggregation: influence of the hematocrit (1980) (50)
Hypergammaglobulinemia can be associated with a positive direct antiglobulin test, a nonreactive eluate, and no evidence of hemolysis (1988) (48)
Maternal immunization to Gov system alloantigens on human platelets (1997) (48)
Studies investigating platelet aggregation and release initiated by sera from patients with thrombotic thrombocytopenic purpura. (1987) (47)
Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. (2010) (46)
The Serological Investigation of Patients with Autoimmune Thrombocytopenia (1995) (44)
The amount of platelet-bound albumin parallels the amount of IgG on washed platelets from patients with immune thrombocytopenia (1983) (44)
Neonatal alloimmune thrombocytopenia: Spontaneous in utero intracranial hemorrhage (1988) (43)
A prospective study to determine the safety of omitting the antiglobulin crossmatch from pretransfusion testing (1992) (42)
Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. (2005) (42)
Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction (2002) (42)
Abnormal platelet function and arachidonate metabolism in chronic idiopathic thrombocytopenic purpura. (1981) (42)
The Role of Plasma from Platelet Concentrates in Transfusion Reactions (1995) (41)
Factor V Leiden and Thrombotic Complications in Heparin-induced Thrombocytopenia (1998) (41)
Platelet IgG Fc receptor (1987) (41)
Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia (2010) (40)
The use of well‐characterized sera for the assessment of new diagnostic enzyme‐immunoassays for the diagnosis of heparin‐induced thrombocytopenia (2010) (39)
Diagnosis of heparin-induced thrombocytopenia. Still a journey, not yet a destination. (1995) (39)
Platelet specific alloantigens on the platelet glycoprotein Ia/IIa complex (1989) (38)
Current controversies concerning the measurement of platelet-associated IgG. (1990) (38)
Splenic radiation for corticosteroid-resistant immune thrombocytopenia. (1992) (37)
Antiplatelet agents: rationale and results. (1983) (37)
The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta‐analysis of a diagnostic test (2019) (37)
Impaired reticuloendothelial function in patients treated with methyldopa. (1985) (36)
The reversible binding of vinblastine to platelets: implications for therapy. (1981) (36)
Serotonin‐release assay‐negative heparin‐induced thrombocytopenia (2020) (36)
ABH antigens on human platelets: expression on the glycosyl phosphatidylinositol-anchored protein CD109. (1998) (35)
Failure of pulse high‐dose dexamethasone in chronic idiopathic immune thrombocytopenia (1997) (32)
Investigation of human platelet alloantigens and glycoproteins using non-radioactive immunoprecipitation. (1993) (32)
Use of intravenous gammaglobulin as an immune replacement and an immune suppressant. (1989) (31)
Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex. (2008) (31)
A phase‐II sequential case‐series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab (2015) (30)
The amount of blood group A substance on platelets is proportional to the amount in the plasma (1982) (30)
111In-oxine platelet survivals in thrombocytopenic infants. (1987) (30)
Analyses of cellular multimerin 1 receptors: in vitro evidence of binding mediated by αΙΙbβ3 and αvβ3 (2005) (30)
Heparin-induced thrombocytopenia. (1986) (29)
Sex-related differences in platelet aggregation: influence of the hematocrit. (1980) (29)
Comparison of the measurement of surface or total platelet‐associated IgG in the diagnosis of immune thrombocytopenia (1985) (28)
Laboratory abnormalities in thrombotic thrombocytopenic purpura. Canadian Apheresis Group. (1998) (28)
Prostaglandin I2 (prostacyclin). (1980) (28)
The effect of rituximab on anti‐platelet autoantibody levels in patients with immune thrombocytopenia (2017) (28)
PLATELET AUTOANTIBODIES IN SEPTICAEMIA (1985) (27)
A review of randomized controlled trials using therapeutic apheresis. (2002) (27)
Relationship between platelet aggregating factor and von Willebrand factor in thrombotic thrombocytopenic purpura (1987) (27)
HLA‐DR expression by platelets in acute idiopathic thrombocytopenic purpura (1992) (27)
Pitfalls in the diagnosis of heparin‐Induced thrombocytopenia: A 6‐year experience from a reference laboratory (2015) (26)
Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition (2008) (26)
The amount of blood group A substance on platelets is proportional to the amount in the plasma. (1982) (26)
The amount of platelet-bound albumin parallels the amount of IgG on washed platelets from patients with immune thrombocytopenia. (1983) (26)
The measurement of platelet-bound immunoglobulins: an overview of the methods and the biological relevance of platelet-associated IgG. (1983) (26)
Sex related differences in platelet function: the effect of aspirin. (1982) (25)
A blinded study of bone marrow examinations in patients with primary immune thrombocytopenia (2013) (25)
The clinical management of heparin-induced thrombocytopenia. (1999) (25)
Serum-induced platelet procoagulant activity: an assay for the characterization of prothrombotic disorders. (1999) (24)
The relationship among platelet-associated IgG, platelet lifespan, and reticuloendothelial cell function. (1984) (23)
Anticonvulsant-induced marrow suppression and immune thrombocytopenia. (1988) (23)
Methyldopa-induced autoantibodies against red blood cells. (1988) (23)
Novel treatments for immune thrombocytopenia. (2014) (23)
Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin‐induced thrombocytopenia (2019) (23)
The diagnostic value of the fibrinogen/fibrin fragment E antigen assay in clinically suspected deep vein thrombosis. (1982) (22)
Isolation and characterization of cysteine proteinase in thrombotic thrombocytopenic purpura (1996) (22)
Analyses of cellular multimerin 1 receptors: in vitro evidence of binding mediated by alphaIIbbeta3 and alphavbeta3. (2005) (22)
Assessing the effectiveness of whole blood–derived platelets stored as a pool: a randomized block noninferiority trial (2005) (22)
How do we diagnose immune thrombocytopenia in 2018? (2018) (22)
An algorithm for resolving ‘indeterminate’ test results in the platelet serotonin release assay for investigation of heparin‐induced thrombocytopenia (2008) (22)
In vitro evaluation of prestorage pooled leukoreduced whole blood–derived platelets stored for up to 7 days (2005) (22)
Difficulties in establishing the diagnosis of immune thrombocytopenia: An agreement study (2016) (21)
Quantitation of red cell membrane associated immunoglobulin in children with Plasmodium falciparum parasitaemia (1983) (21)
Measurement of platelet-associated IgG in animal models of immune and nonimmune thrombocytopenia (1987) (21)
Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Canadian Apheresis Study Group. (1992) (20)
The quantitation of platelet-associated IgG on cohorts of platelets separated from healthy individuals by buoyant density centrifugation (1982) (20)
Granulocytes do not have surface ABO antigens (1985) (20)
Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects (2020) (20)
Comparison of the haemorrhagic effects of porcine and bovine heparin in rabbits. (1979) (19)
Heparin-induced thrombocytopenia. Diagnosis, natural history, and treatment options. (1998) (19)
New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. (2009) (18)
Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: will recent insight into pathogenesis translate into better treatment? (2002) (18)
Dissociation between the level of von Willebrand factor‐cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura (2004) (18)
Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia (2016) (18)
Megakaryocyte apoptosis in immune thrombocytopenia (2018) (18)
Lessons from vaccine-induced immune thrombotic thrombocytopenia (2021) (18)
Inhibition of Microsurgical Thrombosis by the Platelet Glycoprotein IIb/IIIa Antagonist SR121566A (2003) (18)
Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura (2012) (18)
Heparin-induced thrombocytopenia: an iceberg rising. (2005) (17)
The development and application of a serum assay for platelet-bindable IgG (S-PBIgG). (1981) (17)
Sex-related differences in the efficacy of acetylsalicylic acid (ASA) : the absorption of ASA and its effect on collagen-induced thromboxane B2 generation. (1981) (16)
Thrombocytopenia during Pregnancy (1988) (16)
Thrombotic thrombocytopenic purpura. (1992) (15)
Correlation of a quinidine-induced platelet-specific antibody with development of thrombocytopenia. (1985) (14)
The prenatal identification of fetal compatibility in neonatal alloimmune thrombocytopenia using amniotic fluid and variable number of tandem repeat (VNTR) analysis (1995) (13)
FcγRIIa proteolysis as a diagnostic biomarker for heparin‐induced thrombocytopenia (2013) (13)
Idiopathic immune thrombocytopenic purpura: an update. (2000) (13)
Platelet‐Activating Antibodies Are Detectable at the Earliest Onset of Heparin‐Induced Thrombocytopenia, With Implications for the Operating Characteristics of the Serotonin‐Release Assay (2018) (13)
Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial. (2020) (13)
Platelet and red cell clearance is determined by the interaction of the IgG and complement on the cells and the activity of the reticuloendothelial system. (1987) (13)
Producing megakaryocytes from a human peripheral blood source (2016) (13)
Development of a high-yield expression and purification system for platelet factor 4 (2018) (13)
Spurious hyperkalaemia associated with severe thrombocytosis and leukocytosis (1991) (12)
The use of anti‐D to improve post‐transfusion platelet response: a randomized trial (1995) (12)
Multimerin: A Multimeric Protein Stored in Platelet Alpha-granules. (1995) (12)
Management of the pregnant patient with idiopathic thrombocytopenic purpura. (1983) (12)
A human monoclonal autoantibody to platelet glycoprotein IIb derived from normal human lymphocytes. (1992) (12)
Advances in the diagnosis and management of ITP. (1985) (11)
The production of human monoclonal antiplatelet auto‐antibodies derived from human lymphocytes of normal origin: reactivity to DNA, anionic phospholipids and platelet proteins (1992) (11)
PATHOPHYSIOLOGY OF HEPARIN‐INDUCED THROMBOCYTOPENIA (1992) (11)
Inappropriate antidiuretic hormone complicating histiocytic lymphoma. (1979) (11)
Alloimmune neonatal thrombocytopenia associated with incidental maternal thrombocytopenia (1990) (11)
Acute Thrombocytopenia and Thrombosis (1987) (10)
Perinatal thrombocytopenia. (1995) (10)
The association between platelet activation and FcγRIIa proteolysis (2011) (10)
Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia. (2020) (10)
Idiosyncratic drug-induced thrombocytopenia. (1988) (10)
A comparative study of platelet factor 4‐enhanced platelet activation assays for the diagnosis of heparin‐induced thrombocytopenia (2021) (10)
Platelet survival studies, An overview of the factors affecting the efficiency and reliability of platelet radiolabeling (1986) (10)
Antibody binding to megakaryocytes in vivo in patients with immune thrombocytopenia (2015) (9)
Heparin-induced thrombocytopenia: what the serologists have taught us. (1996) (9)
Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score. (2018) (9)
SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia (2021) (9)
A simple and rapid competitive enzyme‐linked immunosorbent assay to identify HPA‐1a (PlA1)‐negative donor platelet units (1996) (9)
Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology (2021) (9)
A prospective study measuring the development of antibodies against platelet factor 4–heparin in healthy males after exposure to heparins (2012) (9)
Intravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura (2007) (9)
Assessment of the optimal anticoagulant solution for storage of whole blood samples prior to measurement of platelet‐associated IgG (1982) (8)
Three examples of Rh haemolytic disease of the newborn with a negative direct antiglobulin test (1995) (8)
A novel congenital haemostatic defect: combined factor VII and factor XI deficiency (1992) (8)
Substitution of the “group-and-screen” for the full crossmatch in elective operations (1983) (7)
The quantitation of platelet-associated IgG on cohorts of platelets separated from healthy individuals by buoyant density centrifugation. (1982) (7)
Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia (2016) (7)
Platelet-Activating Anti-Platelet Factor 4/Polyanion Antibodies without Preceding Heparin Therapy: A Transient Autoimmune Disorder Resembling Heparin-Induced Thrombocytopenia (“Spontaneous HIT”). (2006) (7)
A platelet viability assay (PVA) for the diagnosis of heparin-induced thrombocytopenia (2019) (7)
Development of a serological assay to identify SARS-CoV-2 antibodies in COVID-19 patients (2020) (7)
Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S (2022) (7)
Platelet fragments do not contribute to elevated levels of platelet associated IgG (1985) (7)
Laboratory Testing for Hit Antibodies: How Much Class Do We Need?. (2004) (7)
PROTEOLYTIC DEGRADATION OF HIGH MOLECULAR WEIGHT KININOGEN IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA (1997) (6)
The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia (2022) (6)
Platelet transfusions―a critical appraisal (1983) (6)
Increased cytotoxic potential of CD8+ T cells in immune thrombocytopenia (2019) (6)
Bacterial infection‐associated improvement of platelet counts in two patients with chronic and unresponsive idiopathic thrombocytopenic purpura with normal platelet survival studies (1995) (6)
Neonatal thrombocytopenia. (1984) (6)
Blood transfusion : a conceptual approach (1984) (6)
Platelet Activating Immune Complexes Identified in COVID-19 Associated Coagulopathy (2020) (6)
Thrombotic Thrombocytopenic Purpura: Mechanism for Effectiveness of Plasmapheresis (1979) (6)
The platelet aggregating factor(s) of thrombotic thrombocytopenic purpura. (1990) (6)
The use of electron microscopy in the investigation of the ultrastructural morphology of immune thrombocytopenic purpura platelets. (2000) (6)
A comparison of the quantitative ristocetin von Willebrand factor assay by using fresh and fixed platelets. (1980) (6)
A study of the bioavailability and platelet inhibitory effects of a new enteric-coated acetylsalicylic acid preparation. (1984) (5)
RhD status of a fetus at risk for haemolytic disease with a discrepant maternal DNA‐based RhD genotype (1999) (5)
Measurement of endogenous and exogenous alpha‐granular platelet proteins in patients with immune and nonimmune thrombocytopenia (1999) (5)
Dermatomyositis associated with platelet thrombi formation and responsive to antiplatelet therapy. (1983) (5)
Multimerin (1995) (5)
New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses (2009) (5)
Acute thrombocytopenia and thrombosis. Heparin-induced thrombocytopenia and thrombotic thrombocytopenic purpura. (1987) (5)
Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin‐induced thrombocytopenia (2018) (5)
Adverse reactions in healthy blood donors undergoing plasmapheresis. (1990) (4)
Treatment of Heparin-Induced Thrombocytopenia (2013) (4)
Digitalis toxicity manifested by dysphagia. (1978) (4)
The production of platelet controls for assays quantitating platelet‐associated IgG (1983) (4)
Hemolysis and Thrombocytopenia (2002) (4)
Measurement of platelet-associated IgG in animal models of immune and nonimmune thrombocytopenia. (1987) (4)
Immune haemolytic anaemia and thrombocytopenia: drugs and autoantibodies. (1991) (4)
The Mcmaster ITP Registry: Assessing the Prevalence, Clinical and Laboratory Features of Immune Thrombocytopenia (2014) (3)
Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale (2019) (3)
Antibody-mediated platelet activation. (1993) (3)
The mechanism of action of high-dose IgG in idiopathic thrombocytopenic purpura (2002) (3)
Platelet-associated IgG in septicemia. (1979) (3)
Testing for heparin‐induced thrombocytopenia: are we there yet? (2007) (3)
Monoclonal antibodies against platelet glycoproteins. (1993) (3)
Performance characteristics of platelet autoantibody testing for the diagnosis of immune thrombocytopenia using strict clinical criteria (2021) (3)
The effect of aspirin on the size of the hemostatic plug. (1983) (2)
Heparin Associated Thrombocytopenia Is Not A Typical Drug Induced Thrombocytopenia (1981) (2)
Rituximab for the Treatment of Adults with ITP: A Systematic Review. (2005) (2)
Heparin-induced skin necrosis. (1993) (2)
The Efficacy of H. pylori Eradication Therapy in H. pylori-Infected and Uninfected Patients with Immune Thrombocytopenic Purpura: A Systematic Review. (2008) (2)
Calcium-Dependent Cysteine Protease Activity in the Sera of Patients With (2010) (2)
The interaction of ancrod with human platelets. (1999) (2)
Platelet variability index: a measure of platelet count fluctuations in patients with immune thrombocytopenia (2021) (2)
Persistent Impairments in Humoral and Cellular Immunity in Patients with Immune Thrombocytopenia Treated with Rituximab: A Sub-Study of a Randomized Controlled Trial (2012) (1)
Pathogenic Antibodies in Heparin-Induced Thrombocytopenia Specifically Target an Immunodominant Region on Platelet Factor 4 (2019) (1)
Acetylsalicylic Acid for the Prevention and Treatment of Thromboembolic Diseases (2004) (1)
Platelet immunobiology. (1990) (1)
Dealing with drug-induced thrombocytopenia. (1998) (1)
Rabbit Platelets do not Express Fc Receptors for IgG. (1992) (1)
Campylobacter Jejuni and Thrombotic Thrombocytopenic Purpura (1990) (1)
The role of fluid-phase immune complexes in the pathogenesis of heparin-induced thrombocytopenia. (2020) (1)
Thrombocytopenia is Associated With Increased Binding of IgG to Platelets Both In Vivo and In Vitro (2016) (1)
Use of Anticoagulation in Patients with Immune Thrombocytopenia (2017) (1)
A Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients with Relapsed or Refractory TTP (2014) (1)
Reply (2002) (1)
Platelet associated IgG--an overview. (1985) (1)
Intravenous IgG: A New Therapeutic Tool. (1988) (1)
Platelet transfusions. (1979) (1)
Triple Immunosuppressive Therapy in Patients with Chronic Resistant Immune Thrombocytopenic Purpura; a Case Series of 11 Patients. (2004) (1)
Prostaglandin I2 (prostacycin) (2006) (1)
Performance Characteristics of a Novel Platelet Viability Assay for Heparin-Induced Thrombocytopenia (2017) (1)
Current Concepts in the Treatment of Immune Thrombocytopenia (1990) (1)
Treatment of adults with ITP: less may be more (2001) (1)
thrombocytopenic purpura A retrospective, 11-year analysis of obstetrical patients with idiopathic (2013) (1)
An Algorithm for “Indeterminate” Test Results in the Platelet Serotonin Release Assay for Heparin-Induced Thrombocytopenia (HIT). (2006) (1)
OMITTING THE ANTIGLOBULIN CROSSMATCH (1993) (0)
Fluid-Phase Immune Complexes Can Assemble and Activate Platelets in Heparin-Induced Thrombocytopenia (2018) (0)
Frequent association of factor VII defects with other clotting disorders (1992) (0)
SPLENECTOMY FOR RELAPSING THROMBOTIC THROMBOCYTOPENIC PURPURA. AUTHOR'S REPLY (1997) (0)
The Development of a Bacteriophage Expression Vector for Cloning Immunoglobulin Variable Region Genes from B‐Cell Genomic DNA a (1995) (0)
low molecular weight heparin in rabbits The relationship between the hemorrhagic and antithrombotic properties of (2011) (0)
Splenectomy for Relapsing Thrombotic Thrombocytopenic Purpura (1997) (0)
Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura. Author's reply (2002) (0)
Current clinical uses of antiplatelet drugs (2017) (0)
Low Level Platelet-Activating Antibodies in Patients Suspected of Having Heparin-Induced Thrombocytopenia but Testing Negative in the ”Gold Standard” Functional Test (2014) (0)
Perioperative Eltrombopag or Intravenous Immune Globulin for Patients with Immune Thrombocytopenia: A Multicenter Randomized Trial (2019) (0)
The Effect Of Heparin Upon Complement Activation (1980) (0)
Adjudicating the Diagnosis of Immune Thrombocytopenia in a Clinical Research Study (2022) (0)
Megakaryocyte Apoptosis in the Bone Marrow of Patients with Immune Thrombocytopenia (2016) (0)
Understanding Treatment Preferences In Patients with Primary Immune Thrombocytopenia Contemplating Splenectomy: A Qualitative Study (2010) (0)
Heparin-Induced Thrombocytopenia : Laboratory Studies Blood (2005) (0)
Platelets in Thrombotic and Non-thrombotic Disorders: Immune-mediated thrombocytopenia (2002) (0)
Autoantibodies in Patients with ITP Do Not Bind to Patient-Specific Epitopes on Platelet Glycoproteins. (2008) (0)
Spectral Analysis of Platelet Oscillations in Cyclic Thrombocytopenia. (2009) (0)
ENTERAL HYPERALIMENTATION WITH CHEMICALLY DEFINED (2006) (0)
895 CLINICAL IMPACT OF NEONATAL THROMBOCYTOPENIA–A PROSPECTIVE ONE YEAR STUDY (1985) (0)
Intravenous gamma Globulin Does Not Increase RNA Expression of FcgRIIb in Purified Human Monocytes. (2005) (0)
Heparin-induced thrombocytopenia. (1989) (0)
Longitudinal Characteristics of Anti-Platelet Factor 4 Immunoglobulin G in Vaccine-Induced Immune Thrombotic Thrombocytopenia (2022) (0)
Abnormalities In Platelet Arachidonic Acid Metabolism In Chronic Idiopathic Thrombocytopenic Purpura (1981) (0)
Commentary (Crowther/Kelton): Thromboembolic Complications of Malignancy (2005) (0)
Adjudicating the Diagnosis of Immune Thrombocytopenia in a Clinical Research Study (2022) (0)
Emergency Management of Patients with Immune Thrombocytopenia and Severe Bleeding (2017) (0)
Idiosyncratic drug-induced thrombocytopenia. (1986) (0)
Immune thrombocytopenic purpura. (1997) (0)
Passive Transfer of Hepatitis B Core Antibody by Intravenous Immune Globulin in Patients with Immune Thrombocytopenic Purpura. (2009) (0)
Mechanisms of Static and Shear-Induced Platelet Adhesion: Differences in the Adhesion Supported by MMRN1 Comparisons with Other β3 Integrin Ligands. (2005) (0)
Bone Marrow Specimens From Patients with Immune Thrombocytopenia (ITP) Demonstrate Increased Megakaryocyte-Bound IgG and Increased T-Helper Cells (2011) (0)
Incidence of HPA-9b in Testing for Neonatal Alloimmune Thrombocytopenia. (2007) (0)
Clinical and laboratory predictors of fetal and neonatal alloimmune thrombocytopenia (2022) (0)
Thrombocytopenia caused by passive transfusion of anti-glycoprotein (2011) (0)
CHAPTER 10 – Acquired hemolytic anemia (2011) (0)
Thrombocytopenia in pregnancy (2006) (0)
Identifying Drugs Implicated in Drug-Induced Immune Thrombocytopenia Using Levels of Evidence Applied to Laboratory Tests, (2011) (0)
Prevalence and significance of large granular lymphocytes in patients with immune thrombocytopenia. (2022) (0)
A Non-Inferiority Trial of Perioperative Eltrombopag or Intravenous Immune Globulin for Immune Thrombocytopenia (2020) (0)
An Individual Platelet Count Set-Point in ITP: A Concept Learned from Patients with Mild Thrombocytopenia and a Good Response to IVIg or Corticosteroids. (2007) (0)
A Randomized, Double-Blind Study to Assess Serum Transaminase Elevations and Antibody Formation Following Repeat Subcutaneous Dosing of LMWH, UFH or the Novel Anticoagulant M118 in Healthy Volunteer (2009) (0)
Brief Reports Acute calf pain and swelling in the arthritic patient: rupture of a popliteal cyst or deep venous thrombosis? (2006) (0)
Iconography : Novel treatments for immune thrombocytopenia (2014) (0)
Sex Related Differences in Platelet Function : The Effect of Aspirin Blood (2005) (0)
The Utility of Bone Marrow Examinations for the Diagnosis of Immune Thrombocytopenia. (2010) (0)
A Revisit of the Criteria To Define Remission in Patients with Idiopathic Thrombocytopenia Undergoing Splenectomy. (2005) (0)
HIT : an immune disorder or a consumptive coagulopathy ? (2008) (0)
A Comparison of Two Assays for Platelet Antibodies (1979) (0)
receiving antithrombotic prophylaxis with fondaparinux or enoxaparin Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients (2013) (0)
Peripartum Management of Women with Suspected Hereditary Thrombocytopenia. (2007) (0)
In-Oxine Platelet Survivals in Thrombocytopenic Infants (2005) (0)
The HPA-15 (Gov) Platelet Alloantigen System: Allele Frequencies in the Canadian Population. (2005) (0)

This paper list is powered by the following services:

Other Resources About John G. Kelton

en.wikipedia.org

What Schools Are Affiliated With John G. Kelton?

John G. Kelton is affiliated with the following schools:

McMaster University